At the American College of Cardiology meeting on Saturday, troubling information was presented about the drug Tredaptive that calls into question the utility of niacin therapy in cardiovascular patients. Merck has already halted the approval process for the drug, a combination extended release niacin plus lapropipant to stop flushing, due to lack of benefit in heart patients. Researchers are now saying they also found significantly higher rates of bleeding, infections, diabetic complications, and gastrointestinal problems. Some physicians say this may be the end of the road for niacin therapy, while others are not as quick to rule it out just yet. At what point do we determine that a drug’s risks outweigh its potential benefits and other therapies should be considered first?
For more information, go to Reuters
Photo courtesy of [Stuart Miles/freedigitalphotos.net]